Patents by Inventor Sukhjeet Singh
Sukhjeet Singh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11123420Abstract: The present invention relates to field of live attenuated recombinant tetravalent dengue vaccines and methods of producing stable compositions. Present invention specifically relates to a stable composition and methods of using such a stable composition comprising live attenuated recombinant dengue virus, stabilizer, bulking agent and optionally buffering agents, wherein the live attenuated dengue virus is generated from ? 30 and or ? 31 deleted or mutated dengue strains. More specifically, the present invention relates to stabilizers for freeze-dried live attenuated immunogenic and/or vaccine compositions that may comprise, inter alia, dengue virus(es). The invention further relates to stabilized, freeze-dried live attenuated immunogenic and/or vaccine compositions of, dengue virus(es), which may contain these stabilizers. Other aspects of the invention are described in or are evident from the following disclosure, and are within the ambit of the invention.Type: GrantFiled: September 29, 2016Date of Patent: September 21, 2021Assignee: PANACEA BIOTEC LIMITEDInventors: Rajesh Jain, Sukhjeet Singh, Lavit Jambu
-
Publication number: 20190350940Abstract: The present teachings relate to compounds and compositions for treatment of cancers. In some embodiments, the composition comprises a platinum (IV) complex having at least one reacting group for reacting with a functional group on a protein.Type: ApplicationFiled: May 16, 2019Publication date: November 21, 2019Inventors: Rossitza G. Alargova, Mark T. Bilodeau, Richard Wooster, Benoît Moreau, Kerry Whalen, J. Michael Ramstack, Danielle N. Rockwood, Patrick Lim Soo, Sukhjeet Singh, Tsun P. Au Yeung, Charles-Andre Lemelin, Linda M. Custer
-
Patent number: 10342801Abstract: The present teachings relate to compounds and compositions for treatment of cancers. In some embodiments, the composition comprises a platinum (IV) complex having at least one reacting group for reacting with a functional group on a protein.Type: GrantFiled: June 22, 2016Date of Patent: July 9, 2019Assignee: PLACON THERAPEUTICS, INC.Inventors: Rossitza G. Alargova, Mark T. Bilodeau, Richard Wooster, Benoît Moreau, Kerry Whalen, J. Michael Ramstack, Danielle N. Rockwood, Patrick Lim Soo, Sukhjeet Singh, Tsun P. Au Yeung, Charles-Andre Lemelin, Linda M. Custer
-
Publication number: 20180289793Abstract: The present invention relates to field of live attenuated recombinant tetravalent dengue vaccines and methods of producing stable compositions. Present invention specifically relates to a stable composition and methods of using such a stable composition comprising live attenuated recombinant dengue virus, stabilizer, bulking agent and optionally buffering agents, wherein the live attenuated dengue virus is generated from ? 30 and or ? 31 deleted or mutated dengue strains. More specifically, the present invention relates to stabilizers for freeze-dried live attenuated immunogenic and/or vaccine compositions that may comprise, inter alia, dengue virus(es). The invention further relates to stabilized, freeze-dried live attenuated immunogenic and/or vaccine compositions of, dengue virus(es), which may contain these stabilizers. Other aspects of the invention are described in or are evident from the following disclosure, and are within the ambit of the invention.Type: ApplicationFiled: September 29, 2016Publication date: October 11, 2018Inventors: Rajesh JAIN, Sukhjeet SINGH, Lavit JAMBU
-
Publication number: 20180243318Abstract: The present teachings relate to compounds and compositions for treatment of cancers. In some embodiments, the composition comprises a platinum (IV) complex having at least one reacting group for reacting with a functional group on a protein.Type: ApplicationFiled: June 22, 2016Publication date: August 30, 2018Inventors: Rossitza G. Alargova, Mark T. Bilodeau, Richard Wooster, Benoît Moreau, Kerry Whalen, J. Michael Ramstack, Danielle N. Rockwood, Patrick Lim Soo, Sukhjeet Singh, Tsun P. Au Yeung, Charles-Andre Lemelin, Linda M. Custer
-
Publication number: 20180186823Abstract: The present teachings relate to compounds and compositions comprising a platinum (IV) complex having at least one reacting group for reacting with a functional group on a protein, engineered protein, antibody, antibody fragment, peptide, agonist, antagonist, aptamer or any moiety which may be capable of recognizing a selected target cell population, and/or derivatives/analogs/mimics thereof. The platinum (IV) complex may comprise at least one active agent.Type: ApplicationFiled: June 22, 2016Publication date: July 5, 2018Inventors: Sudhakar Kadiyala, Benoît Moreau, Mark T. Bilodeau, Kerry Whalen, Sukhjeet Singh, Richard Wooster, Charles-Andre Lemelin
-
Patent number: 9642808Abstract: Extended release pharmaceutical compositions comprising mycophenolate sodium as the active agent, wherein the said composition exhibits a characteristic release profile when subjected to in-vitro dissolution study, and wherein said mycophenolate sodium is released in a sustained manner in-vivo for a prolonged duration in such quantities that substantially alleviates or at least reduces the chances of causing any associated gastrointestinal side effect(s) without compromising the bioavailability of the said active agent are provided. The present invention also provides process of preparing dosage form compositions and prophylactic and/or therapeutic methods of using such dosage form. The compositions of the present invention are useful for the management such as prophylaxis, amelioration and/or treatment of immunosuppressant indicated disease(s)/disorder(s) especially for the treatment or prevention of organ, tissue or cellular allograft or xenograft rejection, e.g.Type: GrantFiled: August 11, 2008Date of Patent: May 9, 2017Assignee: PANACEA BIOTECH LIMITEDInventors: Rajesh Jain, Sukhjeet Singh, Sampath Kumar Devarajan
-
Patent number: 8551451Abstract: The present invention relates to a combination vaccine comprising a mixture of antigens for protection against diseases such as diphtheria, tetanus, acellular pertussis, and infections caused by Haemophilus influenzae and polio viruses. The present invention also relates to inclusion of antigens for protection against infections caused Hepatitis virus and other pathogens, such that administration of the vaccine can simultaneously immunize a subject against more than one pathogen. The invention in particular relates to a fully liquid stable combination vaccine comprising the antigens as indicated above and the methods for manufacturing the same.Type: GrantFiled: October 23, 2009Date of Patent: October 8, 2013Assignee: Panacea Biotec LimitedInventors: Rajesh Jain, Sukhjeet Singh, Lavit Jambu
-
Publication number: 20110268808Abstract: Orally deliverable dual-release pharmaceutical suspensions, having a first portion comprising an immediate release form of the active in the solution form or granules or suspended form in the vehicle/medium preferably in the solution form and a second portion comprising a sustained-release form of active in the form of microgranules/microparticles suspended in the immediate release fraction of the solulabilised active agent which comprise a core and at least one coat suitable for liquid dosage forms for the administration of the active ingredients, wherein the core comprises at least one active agent(s) or its pharmaceutically acceptable salts, derivatives, isomers, polymorphs, solvates, hydrates, analogues, enantiomers, tautomeric forms or mixtures thereof; optionally at least one water insoluble, and optionally one or more pharmaceutically acceptable excipient(s); and at least one coat comprising at least one pH independent water-insoluble polymer(s) along with one or more pharmaceutically acceptable excipiType: ApplicationFiled: January 8, 2010Publication date: November 3, 2011Applicant: PANACEA BIOTEC LTD.Inventors: Rajesh Jain, Sukhjeet Singh, Sanju Dhawan
-
Publication number: 20110223249Abstract: Extended release pharmaceutical compositions comprising mycophenolate sodium as the active agent, wherein the said composition exhibits a characteristic release profile when subjected to in-vitro dissolution study, and wherein said mycophenolate sodium is released in a sustained manner in-vivo for a prolonged duration in such quantities that substantially alleviates or at least reduces the chances of causing any associated gastrointestinal side effect(s) without compromising the bioavailability of the said active agent are provided. The present invention also provides process of preparing dosage form compositions and prophylactic and/or therapeutic methods of using such dosage form. The compositions of the present invention are useful for the management such as prophylaxis, amelioration and/or treatment of immunosuppressant indicated disease(s)/disorder(s) especially for the treatment or prevention of organ, tissue or cellular allograft or xenograft rejection, e.g.Type: ApplicationFiled: August 11, 2008Publication date: September 15, 2011Inventors: Rajesh Jain, Sukhjeet Singh, Sampath Kumar Devarajan
-
Publication number: 20110206726Abstract: The present invention relates to a combination vaccine comprising a mixture of antigens for protection against diseases such as diphtheria, tetanus, acellular pertussis, and infections caused by Haemophilus influenzae and polio viruses. The present invention also relates to inclusion of antigens for protection against infections caused Hepatitis virus and other pathogens, such that administration of the vaccine can simultaneously immunize a subject against more than one pathogen. The invention in particular relates to a fully liquid stable combination vaccine comprising the antigens as indicated above and the methods for manufacturing the same.Type: ApplicationFiled: October 23, 2009Publication date: August 25, 2011Applicant: PANACEA BIOTEC LIMITEDInventors: Rajesh Jain, Sukhjeet Singh, Lavit Jambu
-
Publication number: 20110195087Abstract: The present invention relates to a combination vaccine comprising a mixture of antigens for protection against diseases such as diphtheria, tetanus, whole cell pertussis and polio. The present invention also relates to inclusion of one or more antigens in the said combination vaccine, for protection against infections caused by Haemophilus influenzae. Hepatitis virus, and other pathogens, such that administration of the vaccine can simultaneously immunize a subject against more than one pathogen. The invention in particular relates to a fully liquid stable combination vaccine comprising the antigens as indicated above and the methods for manufacturing the same.Type: ApplicationFiled: October 23, 2009Publication date: August 11, 2011Applicant: PANACEA BIOTEC LIMITEDInventors: Rajesh Jain, Sukhjeet Singh, Lavit Jambu
-
Publication number: 20110091536Abstract: Oral pharmaceutical compositions comprising dry extract of Euphorbia prostrata from about 0.1% to about 99% by weight wherein the effective average particle size of the dry extract of Euphorbia prostrata is not more than about 500 microns with pharmaceutically acceptable excipient(s) and process(s) for the preparation of such compositions useful for the treatment of anorectal disease and colonic diseases such as hemorrhoids, fissures, cracks, fistulas, abscesses, inflammatory bowel disease and the like are provided. Further, the pharmaceutical compositions of the present invention provides for the administration of a therapeutically and/or prophylactically effective amount of the Euphorbia prostrata wherein the compositions possess properties to control inflammation, prevent capillary bleeding and fragility in mammalians, particularly human beings.Type: ApplicationFiled: May 28, 2009Publication date: April 21, 2011Applicant: PANACEA BIOTEC LTD.Inventors: Rajesh Jain, Sukhjeet Singh, Shilpa Bhasin
-
Publication number: 20110008426Abstract: Modified release pharmaceutical compositions comprising mycophenolate as the active agent or its pharmaceutically acceptable salts, esters, polymorphs, isomers, prodrugs, solvates, hydrates, or derivatives thereof, wherein the said composition exhibits a biphasic release profile when subjected to in-vitro dissolution and/or upon administration in-vivo are provided. The composition provides a drug release in a manner such that the drug levels are maintained above the therapeutically effective concentration (EC) constantly for an extended duration of time. Further, the difference between the maximum plasma concentration of the drug (Cmax) and the minimum plasma concentration of the drug (Cmjn), and in turn the flux defined as ((Cmax?Cmjn)/Cavg) is minimal. The present invention also provides process of preparing such dosage form compositions and prophylactic and/or therapeutic methods of using such compositions.Type: ApplicationFiled: March 4, 2009Publication date: January 13, 2011Inventors: Rajesh Jain, Sukhjeet Singh
-
Publication number: 20100204333Abstract: Pharmaceutical modified release dosage form comprising at least one cyclooxygenase enzyme inhibitor or its pharmaceutically acceptable salts, esters, prodrugs, solvates, hydrates, or derivatives thereof as active agent, with a pharmaceutically acceptable carrier for controlling the release of the cyclooxygenase enzyme inhibitor is provided. The dosage form preferably provides a release of not more than about 60% of the cyclooxygenase enzyme inhibitor in 1 hour and not less than about 75% of the cyclooxygenase enzyme inhibitor after 12 hours when tested in accordance with the dissolution method (I) described herein employing Distilled water with 2.0% Sodium lauryl sulphate as the dissolution medium or in accordance with the dissolution method (II) described herein employing pH 7.0 Phosphate buffer with 2.0% Sodium lauryl sulphate as the dissolution medium or in accordance with the dissolution method (III) described herein employing 0.001 N Hydrochloric acid with 1.Type: ApplicationFiled: July 19, 2006Publication date: August 12, 2010Applicant: PANACEA BIOTEC LTD.Inventors: Rajesh Jain, Kour Chand Jindal, Sukhjeet Singh, Munish Talwar
-
Publication number: 20090099151Abstract: Novel modified release pharmaceutical composition comprising at least one active agent(s); a polymer system in an amount less than about 80% w/w of the composition comprising at least two swellable pH independent polymers wherein at least one is hydrophilic; optionally other pharmaceutically acceptable excipients is provided. Process for preparation of such compositions and methods of using them is also provided. The compositions are formulated into suitable dosage forms that provide therapeutic concentrations of active agent for extended periods of time.Type: ApplicationFiled: June 29, 2006Publication date: April 16, 2009Applicant: PANACEA BIOTEC LTD.Inventors: Rajesh Jain, Kour Chand Jindal, Sukhjeet Singh, Sanjay Boldhane
-
Publication number: 20090099154Abstract: Pharmaceutical sustained release composition comprising at least one active agent(s), or its tautomeric forms, analogues, isomers, polymorphs, solvates, or salts thereof; preferably an antiviral active agent is provided. Also provided is a process of preparation of such composition and method of using them. The sustained release compositions of the present invention are able to deliver the active agent in a desired manner for an extended period of time.Type: ApplicationFiled: June 29, 2006Publication date: April 16, 2009Applicant: PANACEA BIOTEC LTD.Inventors: Rajesh Jain, Kour Chand Jindal, Sukhjeet Singh, Sanjay Boldhane
-
Publication number: 20090088415Abstract: A non-disintegrating, non-eroding, non-bioadhesive and non-swelling oral controlled release pharmaceutical composition and process for preparation of such compositions is provided which comprises at least one high dose water soluble active ingredient, at least one diluent, at least one binder, and a polymer system comprising of at least one release controlling polymer wherein the composition formulated into a suitable dosage form maintains its geometric shape even after the drug has diffused from the dosage form and provides the concentrations of active ingredient above effective levels for extended periods of time, optionally with other pharmaceutically acceptable excipients. The compositions preferably comprise antibiotic(s) as active ingredient, more preferably Amoxicillin or its pharmaceutically acceptable salts, hydrates, polymorphs, esters, and derivatives thereof, most preferably amoxicillin sodium, either alone or in combination with other antibiotic(s).Type: ApplicationFiled: July 6, 2006Publication date: April 2, 2009Inventors: Rajesh Jain, Kour Chand Jindal, Sukhjeet Singh
-
Publication number: 20080261866Abstract: Pharmaceutical compositions comprising of glycosaminoglycan or salts thereof, preferably chondroitin or salts thereof, more preferably chondroitin sulphate, and nonsteroidal anti-inflammatory drug(s) or salts thereof, optionally with pharmaceutically acceptable excipient(s) are described. The compositions of the present invention provide gastrosparing effect in conditions where nonsteroidal anti-inflammatory drug(s) or their salts are used, particularly in mammals. Also provided are process for the manufacture of such novel compositions and method to minimize the nonsteroidal anti-inflammatory drug(s) induced gastric toxicity.Type: ApplicationFiled: January 19, 2005Publication date: October 23, 2008Applicant: PANACEA BIOTEC LTD.Inventors: Rajesh Jain, Kour Chand Jindal, Sukhjeet Singh
-
Publication number: 20080247962Abstract: A novel pharmaceutical composition comprising a mixture of higher primary aliphatic alcohols from (24) to (39) carbon atoms; at least one another component selected from resins and pigments, hydrocarbons, esters, ketones and aldehydes, and phenolic compounds, and HMG CoA reductase inhibitor, its salts, analogs or derivatives thereof, preferably statins, optionally with pharmaceutically acceptable excipients, and process of preparation of such composition is provided. Also provided are method of treatment and use of such composition for reducing abnormal lipid parameters associated with hyperlipidemia.Type: ApplicationFiled: January 19, 2005Publication date: October 9, 2008Applicant: PANACEA BIOTEC LTD.Inventors: Rajesh Jain, Kour Chand Jindal, Sukhjeet Singh